Current treatment status-Undergoing active treatment - Page 7 of 29 Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment Posts on Medivizor

Is thiotepa-based reduced-intensity conditioning effective before cord blood stem cell transplantation?

Is thiotepa-based reduced-intensity conditioning effective before cord blood stem cell transplantation?

Posted by on May 31, 2018 in Leukemia | 0 comments

In a nutshell This study examined the effectiveness of thiotepa-based RIC in leukemia and lymphoma patients undergoing stem cell transplantation. The authors concluded that this treatment improved outcomes compared to standard RIC. Some background Before undergoing stem cell transplantation, patients with lymphoma or leukemia must undergo conditioning...

Read More

Exercise, body composition and fatigue with androgen deprivation therapy

Exercise, body composition and fatigue with androgen deprivation therapy

Posted by on May 22, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to determine whether body composition (lean and fat mass) and exercise had an effect on fatigue levels in men treated with androgen deprivation therapy. The study concluded that fat mass was associated with fatigue, and an increase in lean mass due to exercise successfully reduced fatigue. Some background Androgen...

Read More

Reviewing radiation therapy options for patients with relapsed or persistent DLBCL

Reviewing radiation therapy options for patients with relapsed or persistent DLBCL

Posted by on May 11, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study reviewed several studies involving patients with relapsed or refractory (does not respond to treatment) diffuse large B-cell lymphoma (DLBCL) who received radiation therapy (RT). The authors concluded that RT can improve outcomes and disease control for patients with localized disease. Some background Diffuse large B-cell...

Read More

Sorafenib to improve outcome after transplant for patients with FLT3-ITD acute myeloid leukemia

Sorafenib to improve outcome after transplant for patients with FLT3-ITD acute myeloid leukemia

Posted by on May 1, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the effect of sorafenib (Nexavar) on the outcomes of patients with acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3)–internal tandem duplication (ITD) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study concluded that sorafenib before or after...

Read More